Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marce, S
Right arrow Articles by Colomer, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marce, S
Right arrow Articles by Colomer, D
Haematologica, Vol 91, Issue 7, 895-902
Copyright © 2006 by Ferrata Storti Foundation

Journal Article

Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma

S Marce, M Molina-Arcas, N Villamor, FJ Casado, E Campo, M Pastor-Anglada, and D Colomer

Unitat d'Hematopatologia, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain.

BACKGROUND AND OBJECTIVES: Nucleoside transporters might play a relevant role in the intracellular targeting of many nucleoside analogs used in anticancer therapy. Two gene families (SLC28 and SLC29) encode the two types of human nucleoside transporters, concentrative nucleoside transporter (CNT) and equilibrative nucleoside transporter (ENT) proteins. Chronic lymphocytic leukemia (CLL) cells express both SLC28- and SLC29-related mRNA, although transport function seems to be mostly related to ENT-type transporters. Here we have analyzed the role of nucleoside transporters in nucleoside-derived drug bioavailability and action in mantle cell lymphoma (MCL) cells. DESIGN AND METHODS: The relative amounts of hENT1 and hENT2-related mRNA and protein were analyzed in five MCL cell lines and 20 primary MCL tumors by real-time quantitative reverse transcriptase polymerase chain reaction and western blots. Cell viability, measured by annexin V-FITC staining, and nucleoside-derived drug transport were also studied. RESULTS: MCL cells express higher levels of hENT1 protein than do CLL cells, and a good correlation was found between protein and mRNA levels of hENT1, thus indirectly suggesting that hENT1 might be transcriptionally regulated in MCL cells. More importantly, a significant correlation between these two parameters, drug uptake and sensitivity to gemcitabine, was also observed. INTERPRETATION AND CONCLUSIONS: These results further support the concept that nucleoside transporters are implicated in the therapeutic response to nucleoside analogs, and suggest a particular and novel role for hENT1 in the genotoxic response to selected nucleoside analogs, such as gemcitabine, in MCL cells.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. D. Fowler, J. A. Brown, K. A. Johnson, and Z. Suo
Kinetic Investigation of the Inhibitory Effect of Gemcitabine on DNA Polymerization Catalyzed by Human Mitochondrial DNA Polymerase
J. Biol. Chem., May 30, 2008; 283(22): 15339 - 15348.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Cai, V. L. Damaraju, N. Groulx, D. Mowles, Y. Peng, M. J. Robins, C. E. Cass, and P. Gros
Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells
Cancer Res., April 1, 2008; 68(7): 2349 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
W. Lam, C.-H. Leung, S. Bussom, and Y.-C. Cheng
The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine
Mol. Pharmacol., September 1, 2007; 72(3): 536 - 544.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.